Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 28+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Published

on

<!– Name:DistributionId Value:8740511 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:9aeab6e8-3252-4415-8292-416d46cfd6ad –>

New York, USA, Feb. 01, 2023 (GLOBE NEWSWIRE) — Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 28+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

RRMS is the most common subtype (approximately 87%), which is characterized by unpredictable acute attacks followed by periods of remission. The growing number of patients would raise the market and demand for treatments that may cure the sickness, motivating various firms to spend on studies, research, and development in order to give better treatment alternatives.Significant innovations in the treatment of patients with multiple sclerosis (MS) have primarily addressed the frequency of flare-ups in relapsing-remitting MS (RRMS). With the evolution of technology, there has been good success in MS research, particularly in the creation of novel and diverse treatments and therapies in the clinical trial phases, and some of them are in the final trial phases and might be market-ready. 

DelveInsight’s Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and pipeline relapsing-remitting multiple sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the relapsing-remitting multiple sclerosis pipeline domain.

Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report

Advertisement
Stake.com
  • DelveInsight’s relapsing-remitting multiple sclerosis pipeline report depicts a robust space with 28+ active players working to develop 28+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment. 
  • Key relapsing-remitting multiple sclerosis companies such as Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others are evaluating new drugs for relapsing-remitting multiple sclerosis to improve the treatment landscape.
  • Promising relapsing-remitting multiple sclerosis pipeline therapies in various stages of development include Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.
  • In March 2022, Pipeline Therapeutics is set to commence the Phase Ib/IIa clinical trial of its lead programme, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients.  The move comes after the company obtained clearance for its investigational new drug application from the US Food and Drug Administration (FDA) to launch the trial. An oral, selective muscarinic M1 receptor antagonist, PIPE-307, is being developed for restoring myelin to treat MS.
  • In July 2021, InnoCare received $125 million upfront in return for sharing rights to orelabrutinib, an orally-active BTK drug that can cross the blood-brain barrier and penetrate the central nervous system. It is currently in a phase 2 trial for relapsing-remitting multiple sclerosis (RRMS). The deal was back-ended with up to $812.5 million in milestone payments if the drug reaches development, regulatory and commercial milestones, and royalties on any future sales.

Request a sample and discover the recent advances in relapsing-remitting multiple sclerosis treatment drugs @ Relapsing-Remitting Multiple Sclerosis Pipeline Report

The relapsing-remitting multiple sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage relapsing-remitting multiple sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the relapsing-remitting multiple sclerosis clinical trial landscape.

Relapsing-Remitting Multiple Sclerosis Overview

Multiple sclerosis is the most common neurological disorder in young adults, with symptoms typically appearing between the ages of 20 and 40. Multiple sclerosis attacks the central nervous system’s axons, which are protected by myelin, also known as white matter. Relapsing-remitting multiple sclerosis is the most common type, accounting for approximately 85% of all multiple sclerosis patients. It is distinguished by relapses (or exacerbations) of symptoms followed by periods of remission, during which multiple sclerosis symptoms improve or disappear.

There are several unusual and rare types of multiple sclerosis. Some people with relapsing-remitting MS experience various multiple sclerosis symptoms that appear to be linked to specific triggers. Exacerbations (also known as recurrences, relapses, or seizures) are acute flare-ups of multiple sclerosis symptoms or the appearance of new symptoms that last for at least 24 h.

Find out more about relapsing-remitting multiple sclerosis treatment drugs @ Drugs for Relapsing-Remitting Multiple Sclerosis Treatment 

Advertisement
Stake.com

A snapshot of the Relapsing-Remitting Multiple Sclerosis Pipeline Drugs mentioned in the report:

Drugs Company Phase  MoA RoA
IMU-838 Immunic Phase III Dihydroorotate dehydrogenase inhibitors Oral
Fenebrutinib Roche Phase III Agammaglobulinaemia tyrosine kinase inhibitors Oral
Divozilimab Biocad Phase III CD20 antigen inhibitors Intravenous
Vafidemstat Oryzon Genomics Phase II Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors Oral
Temelimab GeNeuro SA Phase II Toll-like receptor 4 antagonists Intravenous
Elezanumab AbbVie Phase II RGMA protein inhibitors Intravenous

Learn more about the emerging Relapsing-Remitting Multiple Sclerosis pipeline therapies @ Relapsing-Remitting Multiple Sclerosis Clinical Trials

Relapsing-Remitting Multiple Sclerosis Therapeutics Assessment

The relapsing-remitting multiple sclerosis pipeline report proffers an integral view of relapsing-remitting multiple sclerosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report 

Advertisement
Stake.com
  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Intravenous, Intradermal, Oral, Subcutaneous, Intramuscular
  • Therapeutics Assessment By Molecule Type: Small Molecule, Gene Therapy, Peptide, Immunotherapy, Cell Therapy
  • Therapeutics Assessment By Mechanism of Action: Dihydroorotate dehydrogenase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Lysine specific demethylase 1 inhibitors, Monoamine oxidase B inhibitors, Toll-like receptor 4 antagonists, RGMA protein inhibitors, CD20 antigen inhibitors
  • Key Relapsing-Remitting Multiple Sclerosis Companies: TG Therapeutics, Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others
  • Key Relapsing-Remitting Multiple Sclerosis Pipeline Therapies: Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.

Dive deep into rich insights for new drugs for relapsing-remitting multiple sclerosis treatment; visit @ Relapsing-Remitting Multiple Sclerosis Medications

Table of Contents

1. Relapsing-Remitting Multiple Sclerosis Pipeline Report Introduction
2. Relapsing-Remitting Multiple Sclerosis Pipeline Report Executive Summary
3. Relapsing-Remitting Multiple Sclerosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Relapsing-Remitting Multiple Sclerosis Clinical Trial Therapeutics
6. Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Pre-registration)
7. Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Phase III)
8. Relapsing-Remitting Multiple Sclerosis Pipeline: Mid Stage Products (Phase II)
9. Relapsing-Remitting Multiple Sclerosis Pipeline: Early Stage Products (Phase I)
10. Relapsing-Remitting Multiple Sclerosis Pipeline Therapeutics Assessment
11. Inactive Products in the Relapsing-Remitting Multiple Sclerosis Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Relapsing-Remitting Multiple Sclerosis Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the relapsing-remitting multiple sclerosis pipeline therapeutics, reach out @ Relapsing-Remitting Multiple Sclerosis Treatment Drugs

Related Reports

Multiple Sclerosis Market

Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.

Advertisement
Stake.com

Multiple Sclerosis Epidemiology Forecast

Multiple Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Multiple Sclerosis Pipeline

Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.

Relapsing Multiple Sclerosis Pipeline

Advertisement
Stake.com

Relapsing Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing multiple sclerosis companies, including ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, among others.

Chronic Progressive Multiple Sclerosis Pipeline

Chronic Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic progressive multiple sclerosis companies, including Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, among others.

Primary Progressive Multiple Sclerosis Pipeline

Primary Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary progressive multiple sclerosis companies, including Atara Biotherapeutics, AB Science, Sanofi, MediciNova, among others.

Advertisement
Stake.com

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Business Consulting

Healthcare Competitive Intelligence Services

Advertisement
Stake.com

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 


Advertisement
Stake.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

MGI Tech and SeqOne Partner to Advance End-to-end Genomic Analysis

Published

on

mgi-tech-and-seqone-partner-to-advance-end-to-end-genomic-analysis

PARIS, June 17, 2024 /PRNewswire/ — MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced the collaboration with SeqOne, a leading provider of AI-driven genomic decision support software, to develop and validate end-to-end genomic analysis solutions from sample to report tailored to the needs of Human Genetics and Pathology labs worldwide.

This collaboration between MGI and SeqOne encompasses three distinct initiatives:
Validating an end-to-end, automated, cost-effective solution for HRD signature with MGI DNBSEQ-G99
The collaboration between a Pathology Reference Lab in Spain, Agilent Technologies, MGI, and SeqOne aims to technically validate a routine workflow leveraging Agilent panels, Magnis lib prep automation, MGI DNBSEQ-G99, and SeqOne somaHRD, a clinically validated HRD signature solution, on 96 samples.
This end-to-end solution for pathology molecular labs will enable high-quality, efficient, and flexible HRD testing worldwide, including Genomic Instability score and BRCA testing.
Enabling and validating SeqOne tertiary analysis solution compatible with MGI Megabolt for Germline Panels, Whole Exome and Whole Genome
MegaBOLT bioinformatics analysis accelerator, self-developed and MPS-concentrated hardware accelerating system by MGI, is set to ensure seamless integration and compatibility with SeqOne’s AI-powered variants identification and analysis solution.
The collaboration aims to combine MegaBOLT and the SeqOne Platform to deliver a versatile, cost-effective, intuitive, and time-saving solution from sample to report, particularly attractive for high-throughput Human Genetics labs.
Validating SeqOne CE-IVD Platform for Germline and Somatic analysis for use with MGI sequencers in routine diagnostics
This technical validation project aims to evaluate the compatibility of the SeqOne Platform with MGI sequencing data. It will validate variant calling performances on a set of reference control samples in terms of QC, sensitivity and precision.
“We are thrilled to announce our collaboration with SeqOne. By combining MGI’s cutting-edge sequencing technology with SeqOne’s innovative genomic analysis Platform, we are poised to deliver real insights and solutions for personalized healthcare,” said Dr. Yong Hou, General Manager of MGI Europe and Africa. “This collaboration underscores our commitment to advancing genomic research and providing clinicians with the tools they need to offer tailored treatments to their patients.”
“This partnership with MGI strongly supports SeqOne’s mission to broaden access to sophisticated genomic analysis, aiming to improve healthcare outcomes,” said Martin Dubuc, CEO, SeqOne. “Molecular laboratories globally are exploring how MGI’s sequencing and bioinformatics technologies can advance next-generation sequencing (NGS) research and diagnostics. We are eager to integrate SeqOne’s CE-IVD Platform with MGI’s offerings, enhancing the quality, sensitivity, and precision of bioinformatic analyses.”
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.
About SeqOne
SeqOne is a fast-growing deep-tech company focused on turning genomic data into medically- actionable insights in oncology and rare and inherited diseases. Our vision is to make personalized healthcare a reality for every patient, everywhere. We are committed to democratizing access to advanced genomic insights, enabling labs of any size, in any location, to offer affordable personalized medicine solutions to patients at scale. We integrate cutting-edge AI and big data technologies to redefine genetic data analysis. Our CE-IVD Platform provides time saving, flexible, and cost-effective decision support, empowering decentralized laboratories worldwide to deliver precision diagnostics.The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. To learn more, please visit www.seqone.com and Linkedin.
Logo – https://mma.prnewswire.com/media/2329841/MGI__Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/mgi-tech-and-seqone-partner-to-advance-end-to-end-genomic-analysis-302173987.html

Continue Reading

Artificial Intelligence

Symphony Talent’s Award-Winning Full-Funnel Talent Acquisition Portfolio Earns Strategic Challenger Status on Fosway 9-Grid™ for Third Consecutive Year

Published

on

symphony-talent’s-award-winning-full-funnel-talent-acquisition-portfolio-earns-strategic-challenger-status-on-fosway-9-grid™-for-third-consecutive-year

NEW YORK and LONDON, June 17, 2024 /PRNewswire/ — Symphony Talent, a global leader in recruitment marketing technology and employer brand services, has been named a Strategic Challenger on the 2024 Fosway 9-Grid™ for Talent Acquisition for the third consecutive year, demonstrating Symphony Talent’s consistent dedication to providing cutting-edge solutions that drive game-changing results for talent acquisition teams worldwide.

“From rapidly evolving technologies to shifting candidate expectations, the TA industry faces many challenges,” says Sven Elbert, Head of Analyst Services at Fosway Group. “A full-funnel talent acquisition solution — that seamlessly aligns employer branding, technology and data analytics to the candidate journey — is essential to address these complexities. Symphony Talent provides a robust framework for meeting the diverse needs of complex, global enterprise-scale clients.”
Empowering TA Teams with Full-Funnel Solutions
Symphony Talent’s extensive portfolio of talent acquisition solutions, including its Brand and Creative Services, Programmatic Media Advertising, Career Sites, CRM, and Assessments, drive outstanding client results by addressing every stage of the talent acquisition funnel. Over 700 global clients leverage Symphony Talent’s innovative technologies and strategic expertise, achieving significant outcomes, such as:
Cutting administrative recruiting tasks by 65%Spending 70% less time managing media spendReducing time spent qualifying talent by 60%Decreasing cost per hire by 25%Filling open positions 30% fasterEnsuring quality hires with a 15% reduction in employee turnover”We are honored to be recognized as a Strategic Challenger on the Fosway 9-Grid™ for the third year in a row,” says Kermit Randa, CEO of Symphony Talent. “This achievement highlights our ongoing commitment to connect clients with innovative, high-impact solutions and data that empower them to navigate the complexities of today’s talent landscape and confidently convert candidates to co-workers.”
Highlights of Symphony Talent’s Achievement:
Innovation and Leadership: Symphony Talent’s continuous recognition as a Strategic Challenger is a testament to its unwavering commitment to innovation and leadership in the talent acquisition industry. The company’s comprehensive suite of solutions, including the award-winning SFX platform, integrates brand and creative services with recruitment marketing technology to streamline the hiring process and enhance candidate experience.Client-Centric Approach: Symphony Talent’s focus on understanding and addressing its clients’ evolving needs has been pivotal in maintaining its strategic position. Symphony Talent ensures clients achieve tangible and measurable outcomes by offering personalized support, detailed implementation schedules, and optimization workgroups.Adaptation to Market Trends: With a deep understanding of the current market dynamics and the challenges faced by talent acquisition teams, Symphony Talent has continuously adapted its offerings to meet these demands. This includes leveraging AI and automation to enhance productivity and providing data-driven insights to optimize recruitment strategies.About the Fosway 9-Grid™
Fosway Group is Europe’s #1 HR industry analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 organisations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone. Visit the Fosway website at www.fosway.com.
About Symphony Talent
Symphony Talent is a recruitment marketing technology and employer brand services company that helps talent acquisition teams execute strategic, innovative candidate interactions. Our award-winning, synergistic technology and brand solutions are designed to deliver outcomes — from reach to retention — that unlock a competitive advantage for clients across the globe, including the world’s leading brands. Visit symphonytalent.com to learn more.
Logo – https://mma.prnewswire.com/media/2287879/ST_Logo_Single_Line_Full_Color__12_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/symphony-talents-award-winning-full-funnel-talent-acquisition-portfolio-earns-strategic-challenger-status-on-fosway-9-grid-for-third-consecutive-year-302173377.html

Continue Reading

Artificial Intelligence

Darwinbox named as a Customers’ Choice in the 2024 Gartner® Peer Insights™ Voice of the Customer for Cloud HCM Suites Report for Enterprises with 1,000+ Employees

Published

on

darwinbox-named-as-a-customers’-choice-in-the-2024-gartner-peer-insights™-voice-of-the-customer-for-cloud-hcm-suites-report-for-enterprises-with-1,000+-employees

DUBAI, UAE, June 17, 2024 /PRNewswire/ — Darwinbox, a global leader in cloud-based HCM solutions, today announced that it has been distinguished as a Customers’ Choice in the 2024 Gartner® Peer Insights™ Voice of the Customer for Cloud HCM Suites for 1,000+ Employee Enterprises.

The Gartner® Peer Insights™ Customers’ Choice distinction is based on feedback and ratings from end-user professionals with experience using the product or service. As of 31 January 2024, Darwinbox received an overall rating of 4.8 out of 5 stars across 141 reviews.
“We believe this distinction, for the third consecutive year, reflects our unwavering commitment to our customers and their success, as well as our dedication to excellence and innovation in the HCM space,” says Jayant Paleti, co-founder, Darwinbox.
Darwinbox has been named a Customers’ Choice for both Large Enterprise (1B – 10B USD) and Midsize Enterprise (50M – 1B USD) segments, showcasing its robust capabilities in handling large-scale operations and its widespread appeal across various business sizes. This recognition underscores the platform’s popularity, driven by its powerful configurability, intuitive design, and agility. An impressive 98% of customers rated Darwinbox 4-stars or higher, highlighting the overwhelming satisfaction with the product.
Furthermore, Darwinbox is recognized as the most customer-friendly enterprise-grade HCM solution globally. The platform distinguishes itself through its ease of implementation and integration, prompt vendor responses, and exceptional technical support, demonstrating Darwinbox’s dedication to quick service and client satisfaction. Notably, 94% of its customers have expressed their willingness to recommend Darwinbox, demonstrating its significant impact and reliability in the enterprise tech landscape.
“What I love is when we need support, the customer service is top-notch – always responsive, solution makers, and always helpful,” HR Business Partner, Media Industry
“Darwinbox has been able to cater to our needs given our diverse business structures and differences in processes,” HR Lead, Manufacturing Sector
Read more reviews
About Darwinbox:
Darwinbox is a leading SaaS-based HR technology platform, empowering organisations to automate HR processes and elevate the employee experience. Rated the highest globally among HCM players on Gartner’s customer review platform, Peer Insights, Darwinbox is trusted by 900+ global enterprises with more than 2.5 million employees spread across 116+ countries.
Photo: https://mma.prnewswire.com/media/2438686/Darwinbox_Voice_of_the_Customer.jpg

View original content:https://www.prnewswire.co.uk/news-releases/darwinbox-named-as-a-customers-choice-in-the-2024-gartner-peer-insights-voice-of-the-customer-for-cloud-hcm-suites-report-for-enterprises-with-1-000-employees-302173015.html

Continue Reading

Trending